S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.40 (-1.54%)
AAPL   120.12 (-1.59%)
MSFT   227.07 (-0.22%)
FB   258.01 (+1.02%)
GOOGL   2,035.44 (+1.19%)
TSLA   621.93 (-4.79%)
AMZN   2,981.00 (-0.80%)
NVDA   495.00 (-3.36%)
BABA   230.60 (-2.40%)
CGC   31.01 (-6.71%)
GE   13.65 (+1.56%)
MU   84.35 (-5.34%)
NIO   39.39 (-5.15%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   224.70 (-1.69%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.40 (-1.54%)
AAPL   120.12 (-1.59%)
MSFT   227.07 (-0.22%)
FB   258.01 (+1.02%)
GOOGL   2,035.44 (+1.19%)
TSLA   621.93 (-4.79%)
AMZN   2,981.00 (-0.80%)
NVDA   495.00 (-3.36%)
BABA   230.60 (-2.40%)
CGC   31.01 (-6.71%)
GE   13.65 (+1.56%)
MU   84.35 (-5.34%)
NIO   39.39 (-5.15%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   224.70 (-1.69%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.40 (-1.54%)
AAPL   120.12 (-1.59%)
MSFT   227.07 (-0.22%)
FB   258.01 (+1.02%)
GOOGL   2,035.44 (+1.19%)
TSLA   621.93 (-4.79%)
AMZN   2,981.00 (-0.80%)
NVDA   495.00 (-3.36%)
BABA   230.60 (-2.40%)
CGC   31.01 (-6.71%)
GE   13.65 (+1.56%)
MU   84.35 (-5.34%)
NIO   39.39 (-5.15%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   224.70 (-1.69%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.40 (-1.54%)
AAPL   120.12 (-1.59%)
MSFT   227.07 (-0.22%)
FB   258.01 (+1.02%)
GOOGL   2,035.44 (+1.19%)
TSLA   621.93 (-4.79%)
AMZN   2,981.00 (-0.80%)
NVDA   495.00 (-3.36%)
BABA   230.60 (-2.40%)
CGC   31.01 (-6.71%)
GE   13.65 (+1.56%)
MU   84.35 (-5.34%)
NIO   39.39 (-5.15%)
AMD   77.79 (-3.80%)
T   28.93 (+0.73%)
F   11.93 (-1.97%)
ACB   9.81 (-6.21%)
DIS   188.05 (-2.19%)
BA   224.70 (-1.69%)
NFLX   511.28 (-1.81%)
BAC   36.52 (+0.27%)
Log in
NASDAQ:BVXV

BiondVax Pharmaceuticals Stock Forecast, Price & News

$3.66
-0.41 (-10.07 %)
(As of 03/4/2021 03:59 PM ET)
Add
Compare
Today's Range
$3.52
Now: $3.66▼
$3.93
50-Day Range
$3.52
MA: $4.77▼
$5.95
52-Week Range
$2.35
Now: $3.66▼
$62.00
Volume7,079 shs
Average Volume1.45 million shs
Market Capitalization$41.56 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Headlines

BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering
February 10, 2021 |  finance.yahoo.com
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares
January 29, 2021 |  finance.yahoo.com
BiondVax Announces Third Quarter 2020 Financial Results & Business Update
January 28, 2021 |  finance.yahoo.com
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares
January 28, 2021 |  finance.yahoo.com
BiondVax Announces Appointment of Amir Reichman as New CEO
January 21, 2021 |  finance.yahoo.com
Why BiondVax Pharmaceuticals Stock Imploded Today
October 31, 2020 |  finance.yahoo.com
Biondvax Pharma's flu vaccine candidate unsuccessful in late-stage study
October 23, 2020 |  seekingalpha.com
/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
October 23, 2020 |  finance.yahoo.com
Biondvax Pharmaceuticals Ltd - ADR
September 2, 2020 |  reuters.com
BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company
September 1, 2020 |  seekingalpha.com
BVXV: Phase 3 Data for Universal Flu Vaccine in Late September to Late October 2020…
August 31, 2020 |  finance.yahoo.com
BiondVax Announces Second Quarter 2020 Financial Results
August 20, 2020 |  finance.yahoo.com
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
August 13, 2020 |  finance.yahoo.com
Keep an eye on the momentum at Biondvax Pharmaceuticals
July 24, 2020 |  uk.finance.yahoo.com
Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views
July 14, 2020 |  www.benzinga.com
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
July 10, 2020 |  www.msn.com
Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here
July 10, 2020 |  www.nasdaq.com
Could Biondvax Pharmaceuticals (NAQ:BVXV) be a turtle trade?
July 10, 2020 |  uk.finance.yahoo.com
Here is What Hedge Funds Think About Nautilus, Inc. (NLS)
July 5, 2020 |  finance.yahoo.com
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
July 1, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BVXV
Previous Symbol
CUSIPN/A
CIK1611747
Webwww.biondvax.com
Phone972-8930-2529
Employees25
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio6.48
Quick Ratio6.48

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($2.88) per share
Price / Book-1.27

Profitability

EPS (Most Recent Fiscal Year)($3.60)
Net Income$-31,600,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-135.18%

Miscellaneous

Outstanding Shares11,354,000
Market Cap$41.56 million
Next Earnings Date6/11/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.50 out of 5 stars

Medical Sector

1559th out of 1,969 stocks

Biological Products, Except Diagnostic Industry

164th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$3.66
-0.41 (-10.07 %)
(As of 03/4/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BiondVax Pharmaceuticals (NASDAQ:BVXV) Frequently Asked Questions

What stocks does MarketBeat like better than BiondVax Pharmaceuticals?

Wall Street analysts have given BiondVax Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BiondVax Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 972,800 shares, an increase of 36.8% from the January 14th total of 710,900 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is currently 0.9 days.
View BiondVax Pharmaceuticals' Short Interest.

When is BiondVax Pharmaceuticals' next earnings date?

BiondVax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, June 11th 2021.
View our earnings forecast for BiondVax Pharmaceuticals.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) posted its quarterly earnings data on Thursday, January, 28th. The company reported ($0.01) earnings per share for the quarter.
View BiondVax Pharmaceuticals' earnings history.

How has BiondVax Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

BiondVax Pharmaceuticals' stock was trading at $6.5350 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BVXV stock has decreased by 42.2% and is now trading at $3.78.
View which stocks have been most impacted by COVID-19.

Who are BiondVax Pharmaceuticals' key executives?

BiondVax Pharmaceuticals' management team includes the following people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 59)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 51)
  • Mr. Elad Mark B.Sc., Eng., M.B.A., Chief Operating Officer (Age 39)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 57)
  • Dr. Shimon Hassin, Chief Admin. Officer
  • Mr. Joshua E. Phillipson, Director of Bus. Devel. & Investor Relations

Who are some of BiondVax Pharmaceuticals' key competitors?

Some companies that are related to BiondVax Pharmaceuticals include Protara Therapeutics (TARA), ERYTECH Pharma (ERYP), Pluristem Therapeutics (PSTI), Idera Pharmaceuticals (IDRA), Protalix BioTherapeutics (PLX), X4 Pharmaceuticals (XFOR), Champions Oncology (CSBR), Genocea Biosciences (GNCA), Aziyo Biologics (AZYO), BiomX (PHGE), Dyadic International (DYAI), La Jolla Pharmaceutical (LJPC), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON) and CytRx (CYTR).
View all of BVXV's competitors.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an initial public offering on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $3.78.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals has a market capitalization of $42.92 million. The company earns $-31,600,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does BiondVax Pharmaceuticals have?

BiondVax Pharmaceuticals employs 25 workers across the globe.

What is BiondVax Pharmaceuticals' official website?

The official website for BiondVax Pharmaceuticals is www.biondvax.com.

Where are BiondVax Pharmaceuticals' headquarters?

BiondVax Pharmaceuticals is headquartered at Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.